EVALUATION OF THE USE AND EFFICACY OF CANNABIDIOL IN THE TREATMENT OF ANXIETY DISORDERS AND DEPRESSION
DOI:
https://doi.org/10.47820/recima21.v6i2.6180Keywords:
cannabidiol; anxiety; depressionAbstract
This review highlights the use of cannabidiol (CBD) as a therapeutic alternative for anxiety disorders and depression, highlighting its interaction with the endocannabinoid system and 5HT1A receptors, responsible for regulating mood and stress. Materials and Methods: This is an integrative literature review of articles published between 2015 and 2024, using the PICO strategy to define the efficacy of CBD compared to placebo and conventional treatments. Results and Discussion: Eleven studies were included, indicating varied results: while some revealed significant reductions in symptoms of anxiety and depression, others showed inconclusive evidence or limited benefits. Conclusion: Although CBD has been shown to be safe and potentially effective, especially in specific formulations and for selected regions, the need for more robust studies is highlighted. Conclusively, CBD is presented as an emerging therapeutic approach, but still lacking comprehensive scientific validation for routine clinical application.
Downloads
References
BERGER, Maximus et al. “Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial.” The Journal of clinical psychiatry, v. 83, 3 aug. 2022. DOI: https://doi.org/10.4088/JCP.21m14130
BLACK, Nicola et al. “Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.” The lancet. Psychiatry, v. 6, n. 12, p. 995-1010, 2019. DOI: https://doi.org/10.1016/S2215-0366(19)30401-8
BLEBEA, Nicoleta Mirela et al. Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use. International Journal of Molecular Sciences, v. 25, n. 8, p. 4204, 2024. DOI: https://doi.org/10.3390/ijms25084204
BONACCORSO, Stefania et al. “Cannabidiol (CBD) use in psychiatric disorders: A systematic review.” Neurotoxicology, v. 74, p. 282-298, 2019. DOI: https://doi.org/10.1016/j.neuro.2019.08.002
BRANDÃO RODRIGUES, Bráulio; ROCHA ALVARENGA, Lara Cristina e AGUIAR, Cárita. Uso terapêutico do canabidiol nos transtornos de ansiedade e insônia. Brazilian Journal of Development, Curitiba, v. 8, n. 12, p. 79140-79152, dec. 2022. DOI: https://doi.org/10.34117/bjdv8n12-152
DAMMANN, Inga et al. “Cannabidiol and its Potential Evidence-Based Psychiatric Benefits - A Critical Review.” Pharmacopsychiatry, vo. 57, n. 3, p. 115-132, 2024. DOI: https://doi.org/10.1055/a-2228-6118
DE SOUSA, Luís Manuel Mota et al. A metodologia de revisão integrativa da literatura em enfermagem. Revista investigação em enfermagem, v. 21, n. 2, p. 17-26, 2017.
DEGENHARDT, Louisa; HALL,Wayne e LYNSKEY, Michael. Exploring the association between cannabis use and depression. Addiction, v. 98, n. 11, p. 1493-504, nov. 2003. DOI: https://doi.org/10.1046/j.1360-0443.2003.00437.x
DEVANE, William Anthony et al. “Determination and characterization of a cannabinoid receptor in rat brain.” Molecular pharmacology, v. 34, n. 5, p. 605-13, 1988. DOI: https://doi.org/10.1016/S0026-895X(25)09876-1
ERCOLE, Flávia Falci; MELO, Laís Samara de; ALCOFORADO, Carla Lúcia Goulart Constant. Revisão integrativa versus revisão sistemática. Reme: Revista Mineira de Enfermagem, v. 18, n. 1, p. 09-11, 2014. DOI: https://doi.org/10.5935/1415-2762.20140001
GARCÍA-GUTIÉRREZ, María S. et al. “Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.” Biomolecules, v. 10, n. 11, p. 1575, 19 nov. 2020. DOI: https://doi.org/10.3390/biom10111575
GUNDUGURTI, Prasad Rao et al. “Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial.” Asian journal of psychiatry, v. 97, 2024. DOI: https://doi.org/10.1016/j.ajp.2024.104073
HILL, Matthew N.; GORZALKA, Boris B. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behavioural pharmacology, v. 16, n. 5-6, p. 333–352, 2005. DOI: https://doi.org/10.1097/00008877-200509000-00006
JAVAID, Syed Fahad et al. Epidemiology of anxiety disorders: global burden and sociodemographic associations. Middle East Current Psychiatry, v. 30, n. 1, p. 44, 2023. DOI: https://doi.org/10.1186/s43045-023-00315-3
KWEE, Caroline M. B. et al. “Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial.” European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, v. 59, p. 58-67, 2022. DOI: https://doi.org/10.1016/j.euroneuro.2022.04.003
LINGE, Raquel et al. “Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors.” Neuropharmacology, v. 103, p. 16-26, 2016. DOI: https://doi.org/10.1016/j.neuropharm.2015.12.017
MASATAKA, Nobuo. “Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders.” Frontiers in psychology, v. 10, n. 8, nov. 2019. DOI: https://doi.org/10.3389/fpsyg.2019.02466
MCINTYRE, Roger S. et al. Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry, v. 22, n. 3, p. 394-412, 2023. DOI: https://doi.org/10.1002/wps.21120
MENDES, Karina Dal Sasso; SILVEIRA, Renata Cristina de Campos Pereira; GALVÃO, Cristina Maria. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto-enfermagem, v. 17, p. 758-764, 2008. DOI: https://doi.org/10.1590/S0104-07072008000400018
ORTIZ, Yuma T.; MCMAHON, Lance R.; WILKERSON, Jenny L. Medicinal cannabis and central nervous system disorders. Frontiers in pharmacology, v. 13, p. 881810, 2022. DOI: https://doi.org/10.3389/fphar.2022.881810
PINTORI, Nicholas et al. THC and CBD: villain versus hero? Insights into adolescent exposure. International Journal of Molecular Sciences, v. 24, n. 6, p. 5251, 2023. DOI: https://doi.org/10.3390/ijms24065251
PRZEMYSŁAW, Adamczyk et al. “Activation of endocannabinoid transmission induces antidepressant-like effects in rats.” Journal of physiology and pharmacology: an official journal of the Polish Physiological Society, v. 59, n. 2, 217-28, 2008.
ROBSON, Philip. “Therapeutic aspects of cannabis and cannabinoids.” The British journal of psychiatry: the journal of mental science, v. 178, p. 107-15. 2001. DOI: https://doi.org/10.1192/bjp.178.2.107
SOUZA, José Diogo S. et al. “Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic.” Frontiers in pharmacology, v. 13, 3 oct. 2022. DOI: https://doi.org/10.3389/fphar.2022.856846
WIECKIEWICZ, Gniewko et al. Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists. Frontiers in Psychiatry, v. 13, 2022. DOI: https://doi.org/10.3389/fpsyt.2022.837946
Downloads
Published
License
Copyright (c) 2025 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
